{"id":"oxycodone-and-naloxone","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"10-30%","effect":"Constipation"},{"rate":"5-20%","effect":"Dizziness"},{"rate":"5-20%","effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:38:08.586990","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Oxycodone's agonism at the mu-opioid receptor leads to analgesia, while naloxone's antagonism reverses opioid-induced respiratory depression. This combination allows for pain relief with a reduced risk of overdose.","oneSentence":"Oxycodone is a mu-opioid receptor agonist, while naloxone is a mu-opioid receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:14.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain"},{"name":"Opioid-induced respiratory depression"}]},"_fixedFields":["pubmed(37)"],"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT06855836","phase":"NA","title":"Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-03-03","conditions":"Overdose","enrollment":588},{"nctId":"NCT05142267","phase":"NA","title":"Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-03-02","conditions":"Opioid Use Disorder, Back Pain, Stress","enrollment":120},{"nctId":"NCT06897917","phase":"PHASE4","title":"Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04","conditions":"Opioid-Induced Constipation, Pain Cancer","enrollment":203},{"nctId":"NCT02454712","phase":"PHASE1","title":"Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2016-11-16","conditions":"Healthy","enrollment":64},{"nctId":"NCT05090280","phase":"PHASE1","title":"Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-12-01","conditions":"Pharmacokinetics","enrollment":111},{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT00929253","phase":"NA","title":"Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2007-09","conditions":"Opiate Addiction","enrollment":170},{"nctId":"NCT03179475","phase":"PHASE4","title":"Targin® for Chronic Pain Management in Patients With Spinal Cord Injury","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2019-09-05","conditions":"Chronic Pain","enrollment":1},{"nctId":"NCT03757455","phase":"NA","title":"ERAS Protocol in Pancreaticoduodenectomy and Total Pancreatectomy","status":"TERMINATED","sponsor":"Tampere University Hospital","startDate":"2020-09-01","conditions":"Pancreatic Cancer, Surgery--Complications, Pancreatic Fistula","enrollment":35},{"nctId":"NCT03768466","phase":"PHASE4","title":"Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2018-11-21","conditions":"Low Back Pain","enrollment":123},{"nctId":"NCT03740243","phase":"PHASE4","title":"Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology","status":"WITHDRAWN","sponsor":"Stony Brook University","startDate":"2018-11-30","conditions":"Opioid-use Disorder","enrollment":""},{"nctId":"NCT01885182","phase":"PHASE3","title":"Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2013-06-01","conditions":"Cancer, Pain","enrollment":232},{"nctId":"NCT02880475","phase":"PHASE1","title":"OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2014-06-01","conditions":"Chronic Pain","enrollment":30},{"nctId":"NCT01109511","phase":"PHASE4","title":"A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"Ullevaal University Hospital","startDate":"2010-03-01","conditions":"Postoperative Pain, Opioid Induced Constipation","enrollment":85},{"nctId":"NCT00513656","phase":"PHASE2","title":"A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2007-09","conditions":"Cancer, Pain, Constipation","enrollment":230},{"nctId":"NCT01971632","phase":"PHASE3","title":"A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2005-01","conditions":"Subjects With Moderate to Severe, Chronic Nonmalignant Pain","enrollment":463},{"nctId":"NCT01438567","phase":"PHASE3","title":"A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-09","conditions":"Pain, Constipation","enrollment":270},{"nctId":"NCT00412152","phase":"PHASE3","title":"Oxycodone-naloxone in Relieving Opioid-related Constipation","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2006-01","conditions":"Pain","enrollment":""},{"nctId":"NCT02680847","phase":"PHASE4","title":"Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-01-21","conditions":"Moderate-severe Pain","enrollment":32},{"nctId":"NCT01313780","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2011-05","conditions":"Cancer","enrollment":128},{"nctId":"NCT01918098","phase":"PHASE3","title":"Targin for Non-cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2013-09-01","conditions":"Non Cancer Pain","enrollment":230},{"nctId":"NCT00679614","phase":"PHASE3","title":"Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Hip Arthroplasty, Knee Arthroplasty, Spinal Anesthesia","enrollment":45},{"nctId":"NCT02032927","phase":"PHASE4","title":"Treatment of Chronic Pain From Osteoarthritis","status":"WITHDRAWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2013-06","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT01571362","phase":"PHASE3","title":"A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Chronic Pain, Low Back Pain, Analgesia","enrollment":410},{"nctId":"NCT01811186","phase":"PHASE4","title":"An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2012-12","conditions":"Chronic Pain","enrollment":261},{"nctId":"NCT02516059","phase":"PHASE4","title":"Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-09-14","conditions":"Postoperative Pain Management, Radical Cystectomy, Epidural Analgesia","enrollment":90},{"nctId":"NCT01675531","phase":"PHASE4","title":"A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2012-12","conditions":"Cancer","enrollment":73},{"nctId":"NCT02321397","phase":"PHASE2, PHASE3","title":"To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2014-11","conditions":"Malignant Pain, Non-malignant Pain","enrollment":155},{"nctId":"NCT01719757","phase":"PHASE4","title":"PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2012-07","conditions":"Cancer","enrollment":359},{"nctId":"NCT02391571","phase":"PHASE3","title":"A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects","status":"COMPLETED","sponsor":"Elite Laboratories, Inc","startDate":"2015-02","conditions":"Withdrawal Symptoms","enrollment":26},{"nctId":"NCT01811238","phase":"PHASE4","title":"An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2012-09","conditions":"Spinal Disorders","enrollment":240},{"nctId":"NCT00734461","phase":"PHASE2","title":"Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2007-08","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT02165930","phase":"PHASE1","title":"Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-07","conditions":"Healthy","enrollment":17},{"nctId":"NCT01838616","phase":"PHASE4","title":"Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2013-04","conditions":"Back Pain, Low Back Pain, Neuropathic Pain","enrollment":367},{"nctId":"NCT01915147","phase":"PHASE2","title":"A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2013-07","conditions":"Severe Chronic Pain","enrollment":108},{"nctId":"NCT01358526","phase":"PHASE3","title":"Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-05","conditions":"Low Back Pain","enrollment":1095},{"nctId":"NCT01812733","phase":"","title":"Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives","status":"COMPLETED","sponsor":"Mundipharma AB","startDate":"2013-06","conditions":"Pain, Opioid Induced Constipation","enrollment":37},{"nctId":"NCT01710904","phase":"","title":"A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain","status":"COMPLETED","sponsor":"Mundipharma CVA","startDate":"2012-09","conditions":"Chronic Severe Pain","enrollment":68},{"nctId":"NCT01427283","phase":"PHASE3","title":"A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":450},{"nctId":"NCT01427270","phase":"PHASE3","title":"Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":455},{"nctId":"NCT01816581","phase":"PHASE4","title":"Oral Oxycodone After Major Cardiac Surgery","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-07","conditions":"Heart; Dysfunction Postoperative, Cardiac Surgery","enrollment":50},{"nctId":"NCT01825447","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Healthy","enrollment":89},{"nctId":"NCT01167127","phase":"PHASE3","title":"Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain","status":"COMPLETED","sponsor":"Mundipharma Pharmaceuticals B.V.","startDate":"2009-06","conditions":"Pain","enrollment":113},{"nctId":"NCT01167699","phase":"PHASE3","title":"Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain","status":"COMPLETED","sponsor":"Mundipharma Pharmaceuticals B.V.","startDate":"2009-06","conditions":"Pain","enrollment":174},{"nctId":"NCT01374763","phase":"PHASE4","title":"A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery","status":"COMPLETED","sponsor":"Kati Järvelä","startDate":"2011-07","conditions":"Postoperative Pain, Opioid Related Disorders","enrollment":165},{"nctId":"NCT00784810","phase":"PHASE4","title":"A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2009-02","conditions":"Osteoarthritis, Back Pain","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"recentPublications":[{"date":"2024 Apr 8","pmid":"38438230","title":"Bioinspired composite packed in blunt needles, integrated microextraction and determination of oxycodone and naloxone in saliva by substrate spray mass spectrometry.","journal":"Analytica chimica acta"},{"date":"2024","pmid":"38036838","title":"Quantitative LC-MS/MS Analysis of Opiates and Opioids in Human Urine.","journal":"Methods in molecular biology (Clifton, N.J.)"},{"date":"2023 Mar 1","pmid":"37753319","title":"Treatment of Opioid Withdrawal Syndrome Triggered by Oxycodone/Naloxone with Dexmedetomidine.","journal":"Journal of hospice and palliative care"},{"date":"2023 Jan 11","pmid":"36674961","title":"Assessment of Neurotoxic Effects of Oxycodone and Naloxone in SH-SY5Y Cell Line.","journal":"International journal of molecular sciences"},{"date":"2022 Oct 16","pmid":"36293936","title":"Oxycodone-Naloxone Combination Hinders Opioid Consumption in Osteoarthritic Chronic Low Back Pain: A Retrospective Study with Two Years of Follow-Up.","journal":"International journal of environmental research and public health"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxycodone and naloxone","genericName":"Oxycodone and naloxone","companyName":"Mundipharma Pharmaceuticals B.V.","companyId":"mundipharma-pharmaceuticals-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone is a mu-opioid receptor agonist, while naloxone is a mu-opioid receptor antagonist. Used for Moderate to severe pain, Opioid-induced respiratory depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}